• ICCM is trading significantly up today, reaching $8.76 after an over 43% surge in after-hours trading.
  • This surge extends recent momentum driven by the company's June 17, 2026, announcement of a 70% increase in U.S. commercial install base for its ProSense® system and a $5.5 million private placement.
  • Additionally, a recent peer-reviewed article on June 23, 2026, highlighted cryoablation's advantages for breast cancer, further supporting positive sentiment.